Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Multicenter, Randomized, Double-blind, Placebo-controlled Study of the Safety and Efficacy of REAMBERIN® (Meglumine Sodium Succinate) Used for Correction of Metabolic Acidosis in Critically Ill Patients

NCT05147051 is registered in ClinicalTrials.gov with POLYSAN Scientific & Technological Pharmaceutical Company as lead sponsor.

NCT NCT05147051
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05147051 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Multicenter, Randomized, Double-blind, Placebo-controlled Study of the Safety and Efficacy of REAMBERIN® (Meglumine Sodium Succinate) Used for Correction of Metabolic Acidosis in Critically Ill Patients
Lead sponsor
POLYSAN Scientific & Technological Pharmaceutical Company
Phase
Phase 2
Overall status
Completed
Start date
June 16, 2021
Completion date
June 22, 2022
Enrollment
140 (actual)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

metabolic acidosis